- Correspondence
- Open access
- Published:
Global burden of thyroid cancer from 1990 to 2021: a systematic analysis from the Global Burden of Disease Study 2021
Journal of Hematology & Oncology volume 17, Article number: 74 (2024)
Abstract
Thyroid cancer (TC) is a significant global healthcare burden. However, the lack of comprehensive data has impeded our understanding of its global impact. We aimed to examine the burden of TC and its trends at the global, regional, and national levels using data stratified by sociodemographic index (SDI), sex, and age. Data on TC, including incidence, mortality, and disability-adjusted life-years (DALYs) from 1990 to 2021, were obtained from the Global Burden of Disease Study 2021. Estimated annual percentage changes (EAPCs) were calculated to assess the incidence rate, mortality, and DALYs trends. The incidence, mortality, and DALYs of TC in 2021 were 249,538 (95% uncertainty interval: 223,290–274,638), 44,799 (39,925–48,541), and 646,741 (599,119–717,357), respectively. The age-standardized incidence rate (ASIR) in 2021 was 2.914 (2.607–3.213), with an EAPC of 1.25 (1.14–1.37) compared to 1990. In 2021, the age-standardized death rate (ASDR) was 0.53 (0.47–0.575) and age-standardized DALYs rate was 14.571 (12.783–16.115). Compared with 1990, the EAPCs of ASDR and age-standardized DALYs rate showed decreasing trends, at − 0.24 (− 0.27 to − 0.21) and − 0.14 (− 0.17 to − 0.11), respectively. Low SDI regions showed the highest ASDR and age-standardized DALYs rate, at 0.642 (0.516–0.799) and 17.976 (14.18–23.06), respectively. Low-middle SDI regions had the highest EAPCs for ASDR and age-standardized DALYs rate, at 0.74 (0.71–0.78) and 0.67 (0.63–0.7), respectively. Females exhibited decreasing trend in ASDR and age-standardized DALYs rate, with EAPCs of − 0.58 (− 0.61 to − 0.55) and − 0.45 (− 0.47 to − 0.42), respectively. In contrast, males showed an increasing trend in ASDR and age-standardized DALYs rate, with EAPCs of 0.41 (0.35–0.46) for both. In high-income regions, most countries with decreased annual changes in deaths experience increasing age-related deaths. Over the past few decades, a notable increase in TC incidence and decreased mortality has been observed globally. Regions characterized by lower SDI, male sex, and an aging population exhibited no improvement in TC mortality. Effective resource allocation, meticulous control of risk factors, and tailored interventions are crucial for addressing these issues.
To the editor
Thyroid cancer (TC) is a common endocrine malignancy with high incidence of lymph node metastasis [1]. The availability of medical resources within regions often dictates the standardization of postoperative follow-up and adjuvant therapies, which consequently affects TC recurrence and metastasis rates [2]. Therefore, holistic understanding of recent TC disease burden and trends requires a global perspective. The Global Burden of Disease (GBD) database provides valuable TC data [3]. We used the latest GBD data (1990–2021) to evaluate TC burden, to provide insight on personalized approaches to alleviate its global impact.
We initially investigated the global TC burden and trends. The incidence, mortality, and DALYs of TC in 2021 were 249,538 (95% uncertainty interval: 223,290–274,638), 44,799 (39,925–48,541), and 646,741 (599,119–717,357), respectively (Table 1). The age-standardized incidence rate (ASIR) in 2021 was 2.914 (2.607–3.213), with an estimated annual percentage change (EAPC) of 1.25 (1.14–1.37). In 2021, the ASDR was 0.53 (0.47–0.575) and age-standardized DALYs rate was 14.571 (12.783–16.115). Both EAPCs for ASDR (− 0.24; − 0.27 to − 0.21) and age-standardized DALYs rate (− 0.14; − 0.17 to − 0.11) showed decreasing trends. High-income North America had the highest ASIR (5.303; 5.075–5.526), whereas Saudi Arabia had the highest overall ASIR (7.131; 5.395–9.331) (Fig. 1A, Table 1 and Table S1). In summary, the 1990–2021 period witnessed a global increase in TC incidence coupled with decreased mortality rates, although this trend exhibited regional differences.
We first analyzed these regional differences using the sociodemographic index (SDI). From 1990 to 2021, the incidence, mortality, and DALYs of TC increased across all SDI regions, similar to the 2019 findings (Fig. 1B) [4]. High and high-middle SDI regions showed higher ASIR than other regions, and the ASIR of 204 countries were positively correlated with the SDI (r = 0.57, p < 0.05) (Fig. 1C, Figure S1, S2). Low SDI regions showed the highest ASDR (0.642; 0.516–0.799) and age-standardized DALYs rate (17.976; 14.18–23.06). Low-middle SDI regions had the highest EAPCs for ASDR (0.74; 0.71–0.78) and age-standardized DALYs rate (0.67; 0.63–0.7) (Table 1). Therefore, healthcare departments in low and middle SDI countries need to be prepared for the potential increase in TC burden as their SDI improves [5].
For sex-based analysis, the incidence, mortality, and DALYs ratio between females and males was 2.03, 1.49, and 1.47 in 2021, respectively (Table S2). From 1990 to 2021, only males showed increasing trends in ASDR and age-standardized DALYs rate, with EAPCs of 0.41 (0.35–0.46) (Table S2, Figure S3). The median male-to-female burden rate ratios of TC for ages 5–70 years increased significantly (p < 0.05) every 10 years across 204 countries (Figure S4). Although TC incidence was lower in males, mortality rates did not improve. Therefore, increased emphasis should be placed on monitoring male patients with TC in the future.
From an age-specific viewpoint, the highest TC incidence was observed in 55–59-years-old, with 19,600.77 (17,266.17–22,578.22) in females and 11,440.96 (9759.37–13,132.14) in males (Fig. 1D). Elderly patients with TC face unique challenges, including declining immunity, comorbidities, and changes in cancer pathology, necessitating further investigation into age-related trends in TC burden [6]. We defined the ratio of disease burden in those aged ≥ 65 years to that in those aged < 15 years as the aging-related disease burden [7]. In 2021, the countries with the lowest rates of age-related incidence, deaths, and DALYs ratio were all from Sub-Saharan Africa (Fig. 1E). Most countries experiencing decreased annual change are located in high-income regions (Fig. 1E, Figure S5). The rising TC incidence and death rates due to aging highlight the need for targeted strategies to manage the increasing burden in older patients, especially in regions with high SDI [8]. The present study is limited by its reliance on global disease data sources, which vary in quality control standards across different regions and statistical agencies [9]. Moreover, the increase in the global population also influenced the number of TC reported in 2021.
In summary, the 1990–2021 period witnessed increased TC incidence coupled with decreased mortality rates. In particular, regions characterized by lower SDI, male sex, and an aging population have emerged as significant contributors to the currently rising TC burden. Thus, targeted international collaborative research is essential to identify the relevant influencing factors and effectively manage the global disease burden of TC.
Availability of data and materials
The data used for these analyses are all publicly available at http://ghdx.healthdata.org/gbd-2021.
References
Chen DW, Lang BHH, McLeod DSA, Newbold K, Haymart MR. Thyroid cancer. Lancet (London, England). 2023;401(10387):1531–44.
Gubbi S, Al-Jundi M, Foerster P, et al. The effect of thyrotropin suppression on survival outcomes in patients with differentiated thyroid cancer: a systematic review and meta-analysis. Thyroid: Off J Am Thyroid Assoc. 2024;34:674.
GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet (London, England). 2024;403(10440):2100–32.
Zhou T, Huang W, Wang X, et al. Global burden of head and neck cancers from 1990 to 2019. iScience. 2024;27(3):109282.
Chaudhri E, Fathi W, Hussain F, Hashmi SK. The increasing trends in cases of the most common cancers in Saudi Arabia. J Epidemiol Global Health. 2020;10(4):258–62.
Zeng PYF, Prokopec SD, Lai SY, et al. The genomic and evolutionary landscapes of anaplastic thyroid carcinoma. Cell Rep. 2024;43(3): 113826.
GBD 2021 Demographics Collaborators. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet (London, England). 2024;403(10440). Available at https://pubmed.ncbi.nlm.nih.gov/38484753/.
Tota JE, Engels EA, Lingen MW, et al. Inflammatory tongue conditions and risk of oral tongue cancer among the US elderly individuals. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42(15):1745–53.
GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet (London, England). 2024;403(10440):2162–203.
Acknowledgements
We sincerely appreciate the exceptional cooperation of our study team members and gratefully acknowledge the significant contributions of the Global Burden of Disease Study.
Funding
This study was supported by grants from the National STI2030-Major Projects of China (2021ZD0201900), National Natural Science Foundation of China (Grant Nos. 81970869, 82171125, and 82371131), Hospital Level Scientific Research Fund Program of Shanghai Sixth People's Hospital (ynts202404 and hlyjkt202325), Shanghai Municipal Commission of Science and Technology (18DZ2260200), Shanghai Science and Technology Innovation Program of Science and Technology Commission (20Y11902100), and Shanghai Shen-Kang Hospital Management Center Project (Grant Nos. SHDC2020CR2044B and SHDC2020CR3056B).
Author information
Authors and Affiliations
Contributions
The corresponding authors are responsible for the authenticity of the data. All authors made a significant contribution to the work reported (i.e., in the conception design or execution of the study, acquisition, analysis, or interpretation of the data, or in all of these areas). All authors contributed to the drafting of the work or revised the article critically for important intellectual content.All authors approved the final version of the manuscript to be published. TJZ and EHZ confirmed the accuracy of the data sources. TJZ and JYZ processed the raw data using software, and TJZ and XTW visualized the data. TJZ and WJH reviewed and edited the manuscript. KMS, HLY and SKY contributed to managing the overall research enterprise.
Corresponding authors
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Zhou, T., Wang, X., Zhang, J. et al. Global burden of thyroid cancer from 1990 to 2021: a systematic analysis from the Global Burden of Disease Study 2021. J Hematol Oncol 17, 74 (2024). https://doi.org/10.1186/s13045-024-01593-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13045-024-01593-y